RhoJ is an endothelially expressed member of the Cdc42 (cell division cycle 42) subfamily of small Rho GTPases. It is expressed in both the developing mammalian vasculature and the vascular beds of a number of adult tissues, with its expression regulated by the endothelial transcription factor ERG (ETS-related gene). RhoJ has been shown to regulate endothelial motility, tubulogenesis and lumen formation in vitro, and modulates the vascularization of Matrigel plugs in vivo. Both vascular endothelial growth factor and semaphorin 3E have been found to affect its activation. RhoJ has been shown to be a focal-adhesion-localized Rho GTPase which can modulate focal adhesion number, actomyosin contractility and activity of Cdc42 and Rac1. The present review discusses the biology of RhoJ with a focus on recent reports of its role in endothelial cells and angiogenesis.
Endothelial cells and angiogenesis
Endothelial cells line blood and lymphatic vessels. They play central roles in haemostasis, the regulation of vascular tone, the transmigration of leucocytes and in angiogenesis. Angiogenesis is the formation of vessels from pre-existing ones; it is fundamentally important during embryonic development and is necessary in both wound healing and the female menstrual cycle in adults. Certain pathologies, including diabetic retinopathy and the growth and metastasis of solid tumours, are also dependent on angiogenesis. Understanding the molecular basis of this process is key in the identification of new molecular targets which could lead to the development of new therapies. Indeed, various modes of targeting the pro-angiogenic factor VEGF (vascular endothelial growth factor) are approved for the treatment of certain types of cancer and age-related macular degeneration [1] . cycle 42) were found to be involved in regulating stress fibres, lamellipodia and filopodia respectively. More recently, roles for Rho GTPases have been identified in a myriad of cellular processes, including cell division, vesicular trafficking and transcription. Various roles for RhoA, Cdc42 and Rac1 in angiogenesis have been identified, including extracellular matrix degradation, migration, proliferation, capillary branching and lumen formation [3] .
We initially identified RhoJ, also known as TCL (TC10-like), as being an endothelially expressed gene through scrutiny of publicly available expression libraries. An endothelial expression pattern was confirmed by isolating RNA from a number of primary cell types, where expression was exclusively found in vein and microvascular endothelial cells [4] . The cDNA of RhoJ/TCL was initially isolated 10 years ago [5] , and, shortly afterwards, mouse orthologues designated TC10β and RhoT were reported [6, 7] . RhoJ belongs to the Cdc42 subfamily of Rho GTPases and is most closely related to TC10/RhoQ. Whereas Cdc42 has a well-characterized role in filopodia formation, TC10 plays a role in insulin-regulated translocation of GLUT4 (glucose transporter 4), and, more recently, has been implicated in regulating exocytic vesicle fusion [8, 9] . In their active form, Cdc42, Rac, TC10 and RhoJ all bind the CRIB (Cdc42, Racinteractive binding) domain [5] .
The potential function of RhoJ was initially interrogated by several groups primarily by expressing da (dominantactive) and dn (dominant-negative) mutant forms in a range of cell types. Data from these experiments suggested that RhoJ plays a role in regulating the actin cytoskeleton as well as in early endocytosis [5, 6, 10, 11] . A role for RhoJ in adipocyte differentiation in vitro was also identified; RhoJ expression was found to be transiently up-regulated during differentiation, and knockdown of its expression inhibited this process [12] . This inhibition was associated with a blockade in mitotic clonal expansion and a reduction in C/EBP (CCAAT/enhancer-binding protein) transcriptional regulator proteins [13] .
We explored the role of RhoJ in endothelial migration and tubulogenesis, and its regulation of the actin cytoskeleton, and mapped its subcellular localization and tissue distribution [14] . There have subsequently been two further reports noting an endothelial expression pattern and characterizing a role for RhoJ in endothelial cell biology [15, 16] . These various studies are discussed below.
Regulation of RhoJ expression and localization
We and others have demonstrated a vascular expression pattern of RhoJ [14] [15] [16] . It was found to be expressed in a range of both mouse and human adult tissues, including heart, skeletal muscle, pancreas and liver, and in some human tumour types [14, 16] ; it was notably absent from tissues and tumours of the digestive tract [14] . Low levels of expression were found in aortic smooth muscle cells and pericytes, indicating that its expression is not endothelium-specific [14, 16] . RhoJ was also identified as endothelially expressed through microarray analyses of sorted mouse neonatal retinal endothelial cells, and it was found to be most highly expressed in the advancing vascular front in the neonatal mouse retina [15] .
Yuan et al. [16] demonstrated that RhoJ is regulated by the ETS family transcription factor ERG (ETS-related gene), and three ERG-responsive elements were identified in the proximal RhoJ promoter. ERG is an endotheliumenriched transcription factor that has been shown previously to regulate the expression of other endothelial restricted genes such as VE-cadherin (vascular endothelial cadherin) [17, 18] .
Examining expression patterns in human, mouse and zebrafish has highlighted species differences in the regulation of RhoJ expression. For example, we found expression in mouse platelets and B-cells, but not in human platelets or a number of human B-cell lines (S. Kaur and V.L. Heath, unpublished work). RhoJ was also expressed in the mouse thymic stroma, as reported previously [19] .
Using whole-mount in situ hybridization, we demonstrated a vascular expression pattern of RhoJ in mouse at day 9.5 of embryonic development, a stage of development at which angiogenesis is occurring [14] . However, the single zebrafish orthologue of RhoJ did not have a vascular staining pattern and instead was transiently expressed in the somites at 24 hpf (hours post-fertilization) ( Figure 1 ) and in the cephalic region at 48 hpf. Morpholino knockdown of zebrafish RhoJ did affect the development of the intersomitic vessels, probably because of defective somite boundaries which would affect guidance of the vessels in this region (S. Kaur and V.L. Heath, unpublished work). Presumably other closely related Rho GTPases, such as the three Cdc42 or one RhoQ orthologues [20] , which we have found to be ubiquitously expressed, could functionally compensate for the endothelial absence of RhoJ in zebrafish endothelial cells.
Epitope-tagged RhoJ localized to early and recycling endosomes, and modifying RhoJ activity via either knockdown or expression of constitutively active RhoJ altered the trafficking of internalized transferrin receptor [11] . We developed polyclonal antisera which showed RhoJ localization to focal adhesions in endothelial cells [14] . We also have observed a vesicular localization pattern of transfected or virally transduced wild-type RhoJ and daRhoJ, particularly when expression levels are very high. Since certain focal adhesion proteins can be internalized by endocytosis, it is possible that high levels of RhoJ drive its localization to intracellular vesicles [21] . We, like de Toledo et al. [11] , have identified a very slight, but reproducible, delay in the recycling of transferrin in RhoJ siRNA (small inhibitory RNA)-treated HUVECs (human umbilical vein endothelial cells), and it is difficult to know what, if any, impact this would have on endothelial motility or tube formation. In terms of a function for RhoJ in endocytosis itself, we have not found any obvious defects in the uptake of acetylated LDL (low-density lipoprotein) or transferrin, or in VEGF-stimulated uptake of VEGFR2 (VEGF receptor 2) in RhoJ siRNA-treated endothelial cells ( [14] and K. Leszczynska and V.L. Heath, unpublished work).
The functions of RhoJ in endothelial cells
Manipulation of endothelial RhoJ expression by using either siRNA or transducing daRhoJ (Q79L) has demonstrated a role for this Rho GTPase in migration, tubulogenesis and lumen formation [14, 16] . RhoJ positively regulated endothelial motility in a scratch wound assay and promoted tubulogenesis. Knockdown resulted in impaired wound closure and tube formation. The images in Figure 2 show inhibition in sprouting from Cytodex beads coated with RhoJ siRNA-transfected endothelial cells compared with beads coated in mock or negative control duplex transfected cells. It was found that daRhoJ expression enhanced wound closure and increased branching in an organotypic coculture assay where endothelial cells are seeded on to confluent layers of fibroblasts. RhoJ knockdown impaired chemotaxis and reduced endothelial proliferation [14] . RhoJ knockdown was also shown to impair lumen formation in endothelial cells embedded in collagen matrices [16] . Endothelial chemotaxis, migration, proliferation and lumen formation are all vital aspects of angiogenesis in vivo, and indeed Matrigel plugs containing RhoJ-specific siRNA duplexes implanted subcutaneously had fewer microvessels compared with controls [16] .
The activity of Rho GTPases can be regulated through activation of a number of cell-surface receptors including receptor tyrosine kinases, G-protein-coupled receptors and integrins. These in turn influence activity of GEFs (guaninenucleotide-exchange factors) and GAPs (GTPase-activating proteins). GEFs are activatory regulators which mediate the exchange of GDP to GTP, whereas GAPs promote the intrinsic GTP hydrolysis of Rho GTPases. In their GTPbound form, Rho GTPases are able to propagate downstream signals by binding and modulating the activity of a number of effector proteins [2] . Insulin was found to rapidly stimulate RhoJ activation in an adipocyte cell line with a maximal induction observed after 1 min. This induction was inhibited by co-transfection of a dominant-interfering CAP (Cblassociated protein) mutant [7] . CAP is an adaptor protein which links the tyrosine kinase activity of the insulin receptor with the GEF C3G [22] .
In order to determine which signals might activate RhoJ in endothelial cells, the recombinant CRIB domain was used to pull down active RhoJ from cellular lysates. Since RhoJ has a role in endothelial motility and tubulogenesis, we tested whether the pro-angiogenic factor VEGF could activate RhoJ. It was found to induce approximately 2-fold increased levels of RhoJ-GTP 15-30 min after stimulation [14] . Fukushima et al. [15] found that VEGF reduced levels of activated RhoJ after the earlier time point of 2 min by 40% at a higher concentration of VEGF; indeed, we also found a very slight reduction in RhoJ-GTP levels after 1 min. This suggests that there might be a biphasic response to VEGF, with an initial transient decrease in RhoJ activity followed by activation at later time points. In contrast, at this early time point, treatment of endothelial cells with the soluble Sema3E (semaphorin 3E) slightly increased levels of RhoJ-GTP [15] .
Sema3E regulates vascular patterning through its binding of the PlexinD1 receptor; during embryonic development, Sema3E is expressed by somites and provides a repulsive cue for the PlexinD1-expressing intersomitic vessels [23] . Fukushima et al. [15] demonstrated VEGF-regulated tip cell expression of PlexinD1 in the developing retinal vasculature in mice. Blockade of PlexinD1 signalling resulted in increased filopodia formation, suggesting that Sema3E-PlexinD1 signalling may provide negative feedback in limiting VEGF-mediated sprouting. Intriguingly, RhoJ knockdown prevented Sema3E-mediated endothelial cell collapse in vitro, indicating that RhoJ may be involved in Sema3E-mediated inhibition of VEGF-driven sprouting. Consistent with this was the observation that Sema3E added to VEGF enhanced RhoJ, but diminished Cdc42 activation, suggesting perhaps that these two Rho GTPases may play opposing roles in filopodia formation in these conditions. In this same study by Fukushima et al. [15] , endothelial overexpression of wild-type RhoJ in transgenic mice was associated with embryonic growth retardation and lethality [15] .
RhoJ modulates the actin cytoskeleton and focal adhesions
The actin cytoskeleton regulates cellular shape, and its regulation is critical to cellular movement which requires both protrusive and contractile events. Actomyosin describes the complex of actin filaments and bipolar arrays of nonmuscle myosin II, and the activity of the myosin can produce a contractile force. Bundles of actomyosin form stress fibres [24] . These stress fibres connect with the extracellular matrix via focal adhesion complexes, and the co-ordinated assembly and disassembly of focal adhesions combined with modulation of the actin cytoskeleton enable cells to migrate [25] . Migrating endothelial cells are crucial in angiogenesis, with the endothelial tip cell guiding the formation of the newly spouting tube in response to a gradient of proangiogenic stimuli [26] .
The Rho GTPases RhoA, RhoB and RhoC regulate stress fibre formation via their activation of ROCK (Rho kinase) I/II (or ROKα/β); ROCK phosphorylates a number of targets resulting in increased MLC (myosin light chain) phosphorylation and increased actomyosin contractility [27] . In the vasculature, fluid shear stress activates RhoA and ROCK, leading to stress fibre formation [28] , a process considered to ensure that endothelial cells remain flat under flow and minimize resistance to shear forces. In tubulogenesis assays, Mavria et al. [29] demonstrated that established tubes have greater levels of phospho-MLC, and that this is reduced upon induction of sprouting. Indeed, inhibition of ROCK or MLC phosphorylation was accompanied by an induction of Rac1-dependent sprouting [30] . This suggests that this earliest stage of the angiogenic process is both accompanied by and requires decreased actomyosin contractility, whereas the stabilization of newly formed vessels requires increased contractility. The effect of either dnRhoA expression or pharmacological inhibition of ROCK has been reported as either promoting [31] or inhibiting [32] [33] [34] angiogenesis in a variety of models. Since inhibiting ROCK activity is likely to promote sprouting, but impede stabilization of the newly formed vessels, it is likely that the balance of these opposing functions may vary between experimental models, giving differing outcomes.
A number of studies have demonstrated that mutant forms of RhoJ can modulate the cytoskeleton in a range of cell types. In fibroblasts, daRhoJ (Q79L) was found to increase localized F-actin (filamentous actin), decrease stress fibres and induce dorsal ruffles, whereas dnRhoJ reduced stress fibres [5] . Monypenny et al. [35] found that siRNA-mediated knockdown of RhoJ expression in mouse embryonic fibroblasts reduced their speed, but did not affect directionality during chemotaxis. In porcine aortic endothelial cells, daRhoJ (Q79L) induced lamellipodia formation, actin bundles and dotted filamentous structures in the lamellipodia, which co-localized with the focal adhesion marker vinculin [10] . In another study, also in porcine aortic endothelial cells, daRhoJ (Q79L) was found to promote the formation of punctate actin-rich adhesion structures known as podosomes [36] . An alternative daRhoJ mutant (G30V) induced neurite outgrowth in vitro in both phaeochromocytoma and neuroblastoma cell lines [6] .
In our experiments, we found that modulating RhoJ activity affected both stress fibres and focal adhesions in migrating endothelial cells, i.e. either sparsely plated cells or cells at the edge of a scratch wound. Knocking down RhoJ expression led to increased numbers of focal adhesions and increased stress fibres, whereas expression of daRhoJ led to the converse. Interestingly, we found no effect on confluent layers of endothelial cells, suggesting that RhoJ perhaps plays a critical role in migrating cells, whereas in cells within a monolayer, the effects of modulating RhoJ expression may be inhibited through signalling from neighbouring cells. Modulation of stress fibres suggested that RhoJ may regulate actomyosin contractility, and indeed it was found that RhoJ knockdown both enhanced endothelial cell-mediated contraction of a type I collagen gel and led to increased phospho-MLC [14] .
Consistent with our findings, Yuan et al. [16] demonstrated that RhoJ knockdown increased levels of RhoA-GTP in endothelial cells grown in three-dimensional collagen matrices. They also found a concomitant decrease in Cdc42 and Rac1 activation and reduced phosphorylation of Pak2 (Pak is p21-activated kinase), Pak4 and B-Raf [16] . These Rho GTPases and kinases play a role in endothelial lumen formation [37, 38] , hence these changes are consistent with a role for RhoJ in this process. RhoJ was strongly associated with Cdc42 in a pull-down experiment, suggesting that they are in the same complex, and it was weakly associated with Jam-B and MT1-MMP (membrane-type 1 matrix metalloproteinase) [16] , proteins also involved in lumen formation [39] .
Inhibitors of both ROCK and myosin II reversed the motility defect of RhoJ siRNA-treated endothelial cells in the scratch wound and chemotaxis assays, and tube formation on Matrigel was also restored [14] . This suggests that RhoJ promotes migration and tubulogenesis by negatively regulating the Rho-and ROCK-mediated actomyosin contractility. These findings are consistent with The activation of RhoJ is regulated via signalling of cell-surface receptors including VEGFR2 and PlexinD1. Active GTP-bound RhoJ inhibits the Rho signalling pathway, which reduces actomyosin contractility, reduces focal adhesion numbers and promotes Rac1 and Cdc42 activation. Active Cdc42 and Rac1 stimulate Pak2 and Pak4 phosphorylation and lumen formation, and active Rac1 promotes sprouting. Actomyosin contractility and focal adhesion turnover are co-regulated, thus the modulation of actomyosin contractility may be secondary to the regulation of focal adhesion turnover by RhoJ, or vice versa.
those of Mavria et al. [29] , who found that decreased contractility is associated with sprouting. RhoJ activity also regulates focal adhesion numbers. Focal adhesion maturation, turnover and actomyosin contractility are closely co-regulated [25] . Components of focal adhesions are able to regulate contractility; for example, integrin-mediated activation of focal adhesion kinase can regulate RhoA activity via recruitment and activation of Rho GAPs and GEFs [40, 41] . Conversely, modulation of myosin II activity can influence focal adhesion size and distribution, with increased contractility being associated with focal adhesion growth and peripheral distribution in an epithelial cell line [42] . Additionally, lamellipodial actomyosin contractility has been shown to initiate focal adhesion assembly [43] . Thus, since RhoJ localizes to focal adhesions, it may regulate actomyosin contractility via dynamic regulation of focal adhesion turnover, or possibly via modulation of RhoA, RhoB or RhoC via focal adhesion-associated Rho GEFs and GAPs. A model for RhoJ regulation is depicted in Figure 3 .
Future perspectives
A number of outstanding questions about the function of RhoJ remain. With regard to its signalling, the GEFs and GAPs that regulate its activity are yet to be identified, as are the effector proteins which play a critical role in its function connecting its activation to actomyosin contractility and focal adhesion regulation. RhoJ in its GTP-bound form is able to bind the CRIB domain, so it has the potential to activate the same targets as Cdc42, Rac1 and TC10 [5] , although, in vivo, the localization of RhoJ will determine its physiological effectors. The C-terminal hypervariable basic region has been shown to be important in determining the membrane compartment in which the Rho GTPase is localized [44] . Fusing this region from RhoJ on to either constitutively active Cdc42 or TC10 resulted in these fusion proteins behaving similarly to constitutively active RhoJ [11] . This suggests that localization is important for the distinct function of this Rho GTPase, and could explain why other CRIB domainbinding Rho GTPases in endothelial cells cannot functionally compensate for the critical role of RhoJ in endothelial motility and tube formation. It will be essential to determine how RhoJ is recruited and localized to focal adhesions.
In vitro, RhoJ promotes a number of cellular processes associated with angiogenesis, yet, in vivo, is expressed in quiescent vessels. Its function in those vessels is unknown and it is not clear why it should be expressed in some vascular beds but not others. Finally, whereas in vivo siRNA knockdown suggests that it plays a role in angiogenesis, a knockout mouse would additionally provide information on its function during development and shed light on the degree of redundancy between this subfamily of Rho GTPases. In conclusion, RhoJ is a newly identified player in regulating endothelial motility and morphogenesis. Understanding its molecular regulation and in vivo function will provide further insight into its role in angiogenesis and endothelial cell biology.
